Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Currently, there are no medications specifically approved to treat bronchiectasis. Per management estimates, nearly a million patients living in the United States, Europe and Japan are affected by the disease. Based on the results and target market size, Insmed expects to submit a regulatory filing for brensocatib in bronchiectasis in fourth-quarter 2024. If approved, the drug will be the first approved treatment for bronchiectasis patients, with a product launch expected in mid-2025. Management expects to ...